#United States #Prolerity Clinical Research #Erica Prowisor #Michael Smith #Marrero

Prolerity Clinical Research Strengthens Management Team

Prolerity Clinical Research, a prominent name in the clinical research sector, has officially announced pivotal management changes that signal its commitment to enhancing operations and patient engagement. On December 4, 2024, Prolerity appointed Erica Prowisor as Executive Vice President of Transformation and Patient Engagement, alongside Michael Smith as Chief Commercial Officer. This strategic move aligns with the company's goals to improve its extensive network of research sites located across Louisiana, Florida, New Jersey, and New York.

In a statement regarding the appointments, Jeff Williams, the CEO of Prolerity, expressed his enthusiasm about the new additions to the management team. He noted, "I could not be more fortunate to have Erica and Michael join the Prolerity management team as we continue to invest in our site management network." Williams emphasized the importance of both executives' expertise in their respective fields, highlighting their roles in driving growth and enhancing patient engagement for the pharmaceutical and biotech research initiatives driven by Prolerity.

Erica Prowisor, with a background as the Senior Vice President of Patients and Provider Networks at Science 37, brings in-depth knowledge of recruitment and patient engagement strategies. She expressed her excitement about her new role, stating, "I am excited about the opportunity to join Prolerity to ensure that we excel at meeting the needs of patients and drug developers." Prowisor plans to innovate recruitment methodologies to enhance the value offered to clients who depend on the clinical services provided by Prolerity's skilled investigators and staff.

On the other hand, Michael Smith, who previously served as Chief Commercial Officer at Javara and has held positions at Syneos Health, highlighted the importance of Prolerity’s reputation in conducting complex clinical trials. He remarked, "Prolerity's group of sites has built a strong reputation in key challenging areas of research that require focus, experience, and efficient patient access to advance promising treatments into the hands of doctors and patients."

Prolerity's network focuses on a variety of therapeutic areas, significantly in complex Phase I–III trials that encompass conditions like gastroenterology, cardiometabolic diseases, CNS disorders, and liver diseases. A noteworthy aspect of Prolerity's operations includes its New Orleans-based subsidiary, Tandem Clinical Research, renowned for its high-caliber research sites specializing in NASH/NAFLD and neurodegenerative studies. Tandem stands out for its excellence in study feasibility, patient recruitment, and retention processes.

Recently, Tandem has expanded its facilities, evidencing the growth trajectory of Prolerity. The new, state-of-the-art headquarters located in Marrero, Louisiana, spans 12,000 square feet, alongside another 13,000-square-foot facility established in Maitland, Florida, as part of its ClinCloud division. This expansion showcases Prolerity's commitment to enhancing its capabilities and providing significant support for evolving research needs.

Looking ahead, Prolerity aims to continue its mission of advancing medicine and improving the quality of patient care through diligent clinical research. The company is dedicated to serving diverse patient populations while ensuring that drug developers can achieve their study objectives across its expanding network of research sites located across several states. This latest leadership transition is set to play a crucial role in steering Prolerity towards future successes and innovations within the clinical research field.